Ignite Creation Date:
2025-12-25 @ 1:20 AM
Ignite Modification Date:
2026-01-22 @ 3:05 PM
Study NCT ID:
NCT04774393
Status:
RECRUITING
Last Update Posted:
2025-11-07
First Post:
2021-02-24
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-24
Start Date Type:
ACTUAL
Primary Completion Date:
2027-11-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-11-29
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-24
First Submit QC Date:
None
Study First Post Date:
2021-03-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-05
Last Update Post Date:
2025-11-07
Last Update Post Date Type:
ESTIMATED